A recent study suggests that people who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who halt traditional lifestyle plans.
Research printed in a leading health publication demonstrates that while overweight people frequently drop a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Users using these treatments need to be cognizant of the potential of quick rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment weight within about one and a half years.
Comparing Treatments
The study, which examined dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with older methods.
Researchers point out that individuals who shed pounds through diet and exercise typically see a more gradual weight regain—around 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Doctors believe the way of the injections is key to understanding the accelerated regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines recommend the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, due to the likelihood of relapse, the treatment is often life-long.
This view is echoed by pharmaceutical companies, who note that the findings "emphasize the chronic nature of excess weight," comparing it to managing conditions like hypertension.
User Accounts
Users who have discontinued the jabs report a sudden return of appetite.
"It felt as if a trigger activating and I was suddenly extremely hungry," recalled an individual.
This challenge is exacerbated if individuals have not developed sustainable dietary or behavioural changes during therapy.
Widespread Use
Survey data show that millions of people in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent fix and long-term success likely depends on ongoing lifestyle management.
